A recent study by Pease et al., using the National Cancer Data Base from 2010 to 2015, found pCR to be associated with high recurrence scores (RS) > 30 (OR 4.87); however, only 4.3% of the ER+/HER2− cohort had pCR.44 Soran et al. examined 60 pretreatment core needle biopsies in ER+/HER2− patients who received NCT, with no significant correlation between treatment response and RS.45 Thus, OncotypeDx does not seem to be particularly useful for predicting the curative effect of NCT. This evidence concerns the gene ESR1 and cancer.